Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06704347 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XT-150 in Participants With ALS
A Phase 1 study, sponsored by Xalud Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06704347 is a Phase 1 study that has not yet begun recruiting, run by Xalud Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT06704347, a Phase 1 study, has not yet begun recruiting, sponsored by Xalud Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150
Interventions
- BIOLOGICAL XT-150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-11 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06704347
The ClinicalTrials.gov registry entry for NCT06704347 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xalud Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XT-150 is the first listed.
NCT06704347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06704347 about?
NCT06704347 is a clinical study titled "Safety Study of XT-150 in Participants With ALS". This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Ba...
What is the current status of trial NCT06704347?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-11. Estimated completion is 2027-03.
What interventions are being tested in trial NCT06704347?
The interventions under investigation include: XT-150 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06704347?
This trial is sponsored by Xalud Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.